---
author: Norges Bank Investment Management
date: '2025-06-25'
guest: ''
layout: post.njk
source: https://www.youtube.com/watch?v=A_z4Jow0c7A
speaker: Norges Bank Investment Management
tags:
  - pharmaceutical-innovation
  - rd-strategy
  - european-pharma-challenges
  - china-biotech-ecosystem
  - leadership-philosophy
title: 诺华CEO：制药业的创新、挑战与领导力之道
summary: 诺华CEO Vas Narasimhan分享了公司转型为纯粹创新药物公司的战略，强调了AI、细胞与基因疗法等前沿技术在研发中的关键作用。他深入探讨了欧洲制药业面临的政策挑战，以及中国生物制药生态系统的崛起。Narasimhan还阐述了他的领导力哲学，包括培养“受启发、好奇、无层级”的企业文化，以及个人健康管理对领导力的影响。
insight: ''
draft: true
series: ''
category: business
area: market-analysis
project:
  - ai-impact-analysis
  - china-analysis
  - personal-growth-lab
people:
  - Nicolai Tangan
  - Vas Narasimhan
  - Scott Pelton
  - Yuval Noah Harari
  - Steven Pinker
  - Dr. Kelner
  - Draghi
  - Donald Trump
companies_orgs:
  - Novartis
  - Norges Bank Investment Management
  - Alcon
  - Sandoz
  - Isomorphic Labs
  - Google DeepMind
  - Palantir
  - Microsoft Research Labs
  - Amazon
  - Bernstein
products_models:
  - radolyan therapies
  - cell and gene therapies
  - RNA therapeutics
media_books:
  - In Good Company
  - Bhagavad Gita
  - Dao Ching
  - The Power Paradox
  - Nexus
  - Enlightenment Now
  - Financial Times
status: evergreen
---
### 诺华的战略聚焦与创新引擎

**Nicolai Tangan:** 大家好，我是挪威主权财富基金（**Norges Bank Investment Management**: 挪威央行投资管理公司，管理挪威政府全球养老基金）的首席执行官Nicolai Tangan。今天，我非常荣幸能与诺华（**Novartis**: 全球领先的制药公司）的首席执行官Vas Narasimhan共处一室。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Hi everyone, I'm Nicolola Tangan, the CEO of the Norwegian Sovereign Wealth Fund and today I'm in really good company with Vas Narasiman, the CEO of Novartis.</p>
</details>

**Nicolai Tangan:** Vas拥有制药行业中最引人入胜的背景之一。他是一名受过专业训练的医生，在晋升为全球最大制药公司之一的领导者之前，曾在发展中国家抗击肺结核和疟疾的第一线工作。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Vas has one of the most fascinating backgrounds in pharma. He is a trained physician who also worked on the front lines fighting tuberculosis and malaria in developing countries before rising to lead one of the world's largest pharmaceutical companies.</p>
</details>

**Nicolai Tangan:** 我们持有诺华2.3%的股份，价值超过50亿美元，大约相当于每位挪威公民1万挪威克朗。Vas，非常感谢您的加入。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh we own 2.3% of Novartis and that's worth more than $5 billion. Roughly 10,000 Norwegian growner per Norwegian citizen. So Vas big thanks for joining us.</p>
</details>

**Vas Narasimhan:** 很高兴来到这里，Nicolai。简单介绍一下，对于不熟悉诺华的人来说，在10秒钟内，你们的重点领域是什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Great to be here Niclay. Um just uh briefly to uh kick off for those who are not familiar with Novartis in 10 seconds just what are your areas of focus?</p>
</details>

**Vas Narasimhan:** 是的，我们是全球最大的**生物制药**（biopharmaceutical: 利用生物技术生产药物）公司之一，专注于肿瘤学（**oncology**: 研究和治疗肿瘤的医学分支）、心血管疾病（**cardiovascular disease**: 影响心脏和血管的疾病）、神经科学（**neuroscience**: 研究神经系统的科学）和免疫疾病（**immunological diseases**: 免疫系统功能异常引起的疾病）领域的创新药物。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, we're one of the largest biioharmaceutical companies uh in the world focused on innovative medicines in oncology, cardiovascular disease, neuroscience and in imunological diseases.</p>
</details>

**Nicolai Tangan:** 很好。我们稍后会回到其中许多话题。您的背景与许多制药公司首席执行官不同。您认为这如何塑造了您领导诺华的方式？

<details>
<summary>View/Hide Original English</p>
<p class="english-text">Very good. And we'll come back to uh to many of those. Um now you have a different background uh compared to many of the pharma CEOs. How do you think that has shaped your approach to approach to leading Novartis?</p>
</details>

**Vas Narasimhan:** 嗯，我认为这在很多方面都有帮助。我的医生背景和科学背景使我深入了解我们工作的**研发**（R&D: Research and Development，研究与开发）要素。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, I think it's uh it's helped in many dimensions. I mean being coming coming from uh being a physician coming from a scientific background I'm definitely steeped in the R&D elements of the work we do.</p>
</details>

**Vas Narasimhan:** 所以我总是在思考药物如何影响患者，非常注重数据，总是在思考这些药物如何融入临床实践。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I'm always thinking about the medicine how the medicines impact patients very data driven always thinking about how these medicines might fit into clinical practice.</p>
</details>

**Vas Narasimhan:** 鉴于生物制药公司的核心工作是寻找对患者长期有益的突破性创新，我认为这是一个非常有帮助的背景。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And given that the core of what a biioharmaceutical company does is find breakthrough innovations that matter for patients in the long run I think it's a really helpful background.</p>
</details>

**Vas Narasimhan:** 当然，我必须学习很多商业知识。我没有上商学院，必须学习资本配置、资产负债表、损益表和经营业务的所有细节。但我认为医学背景和商业背景的结合对我很有帮助。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You know, I had to learn a lot about business. I didn't go to business school. I had to learn all of the ins and outs of capital allocations and balance sheets, P&Ls, running businesses. But I think the combination of a medical background and business background has served me well.</p>
</details>

**Nicolai Tangan:** 是的，确实如此。坦白说，与医学相比，商业并没有那么困难。所以，我认为您掌握了正确的东西。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, absolutely. Absolutely. Well, to be frank, uh business is is not so difficult compared to medicine. So, I think you you know the right things.</p>
</details>

**Nicolai Tangan:** 在担任首席执行官之前，您曾负责诺华的研发工作。那么，当您接任时，您实施了哪些改变？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Now, you were you were running the uh the R&D efforts at Novartis before taking over as a CEO. So when you um when you took over what kind of changes did you implement?</p>
</details>

**Vas Narasimhan:** 是的，我认为我们所做的最大改变是聚焦公司，我们的想法是诺华最优秀的要素在于我们的研发引擎，它能找到在各种疾病领域取得突破性进展的药物。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, I think the biggest change that we we to we took on was to focus the the company and the idea was our best uh our best elements of Novartis were in our R&D engine finding breakthrough medicines that that move the needle on a range of of different diseases.</p>
</details>

**Vas Narasimhan:** 当时我们是一个庞大的企业集团，涉足**消费者健康**（consumer health: 非处方药、保健品等面向大众市场的产品）、**仿制药**（generics: 专利期满后其他公司生产的相同成分药物）等领域，并通过爱尔康（**Alcon**: 诺华剥离的眼科护理公司）业务涉足**眼科护理**（eye care: 眼睛保健和治疗）和眼科设备。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">At the time we were a sprawling conglomerate and we had areas like consumer health, generics, uh we were in eye care and eye devices with the alcon business.</p>
</details>

**Vas Narasimhan:** 所以我们的想法是专注于成为一家纯粹的**创新药物公司**（pure-play innovative medicines company: 专注于研发和销售新型专利药物的公司）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so the idea was to focus as a pure play innovative medicines company.</p>
</details>

**Vas Narasimhan:** 实际上，这比我预期的要花更长的时间才能实现，大约花了五六年的时间来剥离业务。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Now it took a lot longer than than I expected uh to make that all happen. It took around five six years of spinning businesses.</p>
</details>

**Vas Narasimhan:** 我们剥离了消费者健康业务，分拆了爱尔康（Alcon），分拆了山德士（**Sandoz**: 诺华剥离的仿制药和生物仿制药业务），并出售了我们的罗氏股份。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So we did uh we we got rid of our consumer or moved out of our consumer health business. We spun Alcon, spun Sandos, uh sold our Ro steak.</p>
</details>

**Vas Narasimhan:** 令人难以置信的是，现在当我们审视公司时，我们的市值是2350亿美元。如果加上我们剥离到公开市场的所有这些公司，市值将再增加近1000亿美元。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And what's incredible to me now when you look at our company, our market cap is 235 billion. When you add back all of those companies that we put out uh into the public markets, you add another almost 100 billion to that market cap.</p>
</details>

**Vas Narasimhan:** 所以，最终我们通过聚焦释放了大量价值。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So in the end, we really unlocked a lot of value by focusing.</p>
</details>

**Nicolai Tangan:** 过去，你可能会认为拥有一些非常稳定的收入来源可以抵消**专利悬崖**（patent cliffs: 药物专利到期导致仿制药竞争，销售额大幅下降）等影响。现在，您更像是一家纯粹、精简的制药公司。这给公司内部的态度带来了什么变化？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">In the old days, you could argue that you had some really stable revenue streams which kind of offset uh patent cliffs and so on. Now you are as more a a pure streamlined farmer company. What does that do to the attitudes in the company?</p>
</details>

**Vas Narasimhan:** 我的意思是，曾经有一种信念，认为如果你拥有这些更稳定的业务，就可以抵消我们行业研发生产力的起伏，因为我们自然会面临巨大的专利悬崖，并且必须应对这些专利悬崖。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean it it there was this belief that if you had these more stable businesses that you could offset the peaks and valleys of R&D productivity in our industry because naturally we have large patent cliffs uh and we have to manage through those patent cliffs.</p>
</details>

**Vas Narasimhan:** 但实际上，我们发现情况并非如此。它带来了很多干扰，导致我们无法将资本分配到最有可能产生影响和最大价值的地方。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But actually what we found is something else was happening. a lot of distraction and inability to allocate capital to where we found the most likely impact and the most most value.</p>
</details>

**Vas Narasimhan:** 所以最终，我们在生物制药领域进行了适当的多元化。我们涉足不同的技术平台，并投入了大量资金。我相信我们会讨论这些先进的技术平台。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So in the end, you know, we're appropriately diversified within biioharmaceuticals. We're in different technology platforms and we invest a lot. I'm sure we'll talk about these advanced technology platforms.</p>
</details>

**Vas Narasimhan:** 我们在治疗领域也进行了多元化，但业务线的多元化只会分散我们的精力。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We're diversified in therapeutic areas, but being diversified across business lines just diluted our our effort.</p>
</details>

**Vas Narasimhan:** 最终，如果你回顾诺华的历史，会发现一个非常有趣的事实：我们实际上是通过创新引擎交付了下一波突破性成果，从而成功应对了所有主要的专利到期，而不是因为我们拥有其他业务。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh and in the end, it's really interesting if you look at Novartis' history. We've actually managed through all of our patent experies, major patent experts, not because we had these other businesses, but because our innovation engine actually delivered the next wave of breakthroughs.</p>
</details>

**Vas Narasimhan:** 所以，从某种意义上说，我们必须相信自己，争取胜利，而不是避免失败。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, in a sense, we have to bet on ourselves. Play to win and not play not to lose.</p>
</details>

### 独特的研发策略与前沿技术投资

**Nicolai Tangan:** 您认为你们的研发结构与其他制药公司有所不同吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Do you think you structure your R&D differently uh compared to other pharma companies?</p>
</details>

**Vas Narasimhan:** 我们确实做了一些不同的事情。我们有一个叫做“战略与增长”的部门，几年前我们创建了这个部门。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You know, we do do some things that that that are different. I mean we have a function called strategy uh and growth which we you know created uh a few years back.</p>
</details>

**Vas Narasimhan:** 它由一位来自伯恩斯坦（**Bernstein**: 一家投资研究和资产管理公司）的杰出前华尔街分析师领导，他组建了一个团队，不断审视外部世界，真正引入这些洞察，甚至挑战早期研究人员，质疑他们所做的工作是否真的能推动临床护理的进步。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's run by a wonderful former Wall Street analyst from from Bernstein but has built a a whole team together that relentlessly looks at the outside world really brings in those insights and challenges even early stage researchers on is what they're doing really going to move the needle for for clinical care.</p>
</details>

**Vas Narasimhan:** 所以，我们将这些外部洞察引入到研发的最早期阶段。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So we bring those outside insights even into the earliest stages of of R&D.</p>
</details>

**Vas Narasimhan:** 我们还进行了彻底的聚焦，这是诺华以前一直不擅长的地方。我们曾经涉足过多的治疗领域，过于分散。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We also radically focused and that's something Novartis already always was not really good at. I mean we were in far too many therapeutic areas too diluted.</p>
</details>

**Vas Narasimhan:** 我们现在专注于四个治疗领域，削减了许多其他领域，然后真正建立在我们员工的深厚专业知识之上。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And what we did is we focused on four therapeutic areas cut out a lot of the other areas and then really built on the deep expertise and of our people.</p>
</details>

**Vas Narasimhan:** 我认为这确实带来了成果。现在的问题是，我们如何利用人工智能（AI）和其他技术来超越同行。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think that's really um delivered delivered results. And I think that now the question is how we can use AI and other technologies to to get an edge on our peer set.</p>
</details>

**Vas Narasimhan:** 我想说的另一个独特之处是，我们投资于这些技术平台。我们是**放射配体疗法**（radolyan therapies: 一种利用放射性药物精准靶向并杀死癌细胞的疗法）的世界领导者，也是**细胞和基因疗法**（cell and gene therapies: 通过改变细胞或基因来治疗疾病的疗法）的世界领导者，以及**RNA疗法**（RNA therapeutics: 利用RNA分子作为药物来调节基因表达或蛋白质功能的疗法）的世界领导者之一。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I'd say the one other thing that we do that's unique is we invest in these technology platforms. We're the world leader in radolyan therapies, the world leader in cell and gene therapies, one of the world leaders in RNA therapeutics.</p>
</details>

**Vas Narasimhan:** 这源于一种信念，即你必须不断投资于科学前沿，才能在长期内保持领先。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And that's a belief that you have to keep investing at the cutting edge of science to lead in the long run.</p>
</details>

**Vas Narasimhan:** 所以，如果你思考这个行业在2035年的发展，你必须不断投资于这些前沿技术，这样才能走在前列。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So if you think about where this industry will be in 2035, you have to keep investing in these leading edge technologies so that you're ahead of the curve.</p>
</details>

**Nicolai Tangan:** 如果您要根据吸引力对您的治疗领域进行排名，您会如何排序？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">If you were to rank uh your therapeutic areas according to attractiveness, how would you how would you stack him?</p>
</details>

**Vas Narasimhan:** 这是一个难题，当然，我认为你会使用不同的衡量标准。我的意思是，这些领域中的每一个都有不同的动态。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">That's a tough one. And uh of course uh there there's no different metrics I think you you would you would use. I mean clearly each one of these areas has different dynamics.</p>
</details>

**Vas Narasimhan:** 在心血管疾病领域，你关注的是大规模的**人群健康**（population health: 关注特定人群的健康结果，并努力改善这些结果）问题，并试图找出如何更好地大规模应对心脏病及相关心血管疾病。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean in cardiovascular disease, you're looking at large-scale population health topics and trying to figure out how to better tackle heart disease and related cardiovascular conditions at scale.</p>
</details>

**Vas Narasimhan:** 在神经科学领域，我们非常关注**神经退行性疾病**（neurodegenerative diseases: 神经系统细胞逐渐丧失功能并死亡的疾病，如阿尔茨海默病）和基因驱动的疾病。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">In neuroscience, we're very focused on neurodeenerative diseases and genetically driven diseases.</p>
</details>

**Vas Narasimhan:** 这些是更集中的领域，你正在真正地探索大脑的奥秘。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">These are much more focused areas where you're really, you know, mining the mysteries of of the mind.</p>
</details>

**Vas Narasimhan:** 免疫学也面临着一系列不同的挑战。所以，排名并不容易。我真的认为我们需要在这四个领域都保持强大。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, you know, immunology has a whole set of different challenges. So, it's not easy to to rank. I I really like to think that we need to be strong in all of these these four areas.</p>
</details>

**Vas Narasimhan:** 不过，这确实让我想起了一个重要的旁枝话题，我认为我们在思考本行业的研发时，总是需要提醒自己。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It it does bring to mind an important tangent though that that I think we always have to remind ourselves when we think about R&D uh in our sector.</p>
</details>

**Vas Narasimhan:** 我的意思是，我们所做的工作非常困难。当你思考它时，我们正在试图解开20亿年的细胞进化以及多细胞生物中发生的这些过程的奥秘，并找到一个单一的**药物靶点**（drug target: 药物作用于生物体以产生治疗效果的特定分子），然后实际地作用于该靶点，使其以有效的方式影响人体，这是一项极其艰巨的任务。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean what we do is remarkably hard. I mean when you think about it we are trying to unpack two billion years of evolution of cells and these processes that happen in multisellular organisms and to find a single drug target and then actually drug that target so that it impacts the human body in effective way is an incredibly daunting enterprise.</p>
</details>

**Vas Narasimhan:** 我喜欢告诉我们的人，我们能够做到这一点本身就是一个奇迹，它就握在你的手中。我们能够做到这一点就是一个奇迹，更不用说在200多年里多次做到这一点了。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And the fact that we do it at all I like to tell our people it's a miracle that fits in the palm of your hands. It's a miracle we do this at all, much less doing this multiple times over 200 200 years.</p>
</details>

**Vas Narasimhan:** 所以我认为，提醒自己我们在每个治疗领域或我们所从事的模式中，所做的工作是多么困难，这一点始终很重要。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think it's always important to remind oneself of how hard it is to do the work we do in each one of these therapeutic areas or the modalities that we work in.</p>
</details>

### 科学突破与疾病预防的未来

**Nicolai Tangan:** 嗯，我们生活在一个科学发展日新月异的时代，奇迹比以往任何时候都多，对吗？那么，当您审视您所参与的一切时，您最兴奋的、即将到来的最重要的科学突破是什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, we we're living in a we living at a time where there are more miracles than uh than normal because of uh the way science is moving, right? So when you look at um everything you you are involved with what are the most significant scientific uh breakthroughs on the horizon that you are excited about?</p>
</details>

**Vas Narasimhan:** 是的，我认为有几件事，它们涵盖了整个范围。我认为，就人群健康而言，我们能够越来越早地干预疾病，从而有望阻止疾病发展到晚期，这将变得极其重要。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, I think I think a couple things and and they range across a whole spectrum. I I think on the on one part in terms of population health, our ability to intervene earlier and earlier in disease to hopefully prevent diseases from even getting to late later stages I think will be incredibly important.</p>
</details>

**Vas Narasimhan:** 全球人口结构正变得越来越具挑战性。庞大的老龄化人口，医疗系统承受着巨大压力，由于生育率下降，没有足够的年轻人来为这些医疗系统提供资金。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">uh demography in the world is is only getting more challenging. Huge aging populations, health care systems under strain, uh not enough young people always with the fertility rate falling to actually fund these healthare systems.</p>
</details>

**Vas Narasimhan:** 所以，我们将不得不预防疾病。我们的经验是，你可以更早地进行干预。我们正在非常努力地寻找如何在各种癌症中越来越早地进行干预。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, we're going to have to prevent disease. And our experience is, you know, you can go earlier. We're working very hard to find how can you intervene earlier and earlier in various cancers.</p>
</details>

**Vas Narasimhan:** 我们刚刚在**前列腺癌**（prostate cancer: 男性前列腺发生的癌症）的早期干预方面获得了另一个重要数据集。其理念是，如何进行干预，使癌症不会发展到最终需要住院治疗的阶段。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We just had another important data set in prostate cancer intervening early. And the idea is how how can you intervene so that the the cancer doesn't get to a stage where ultimately it requires hospitalizations.</p>
</details>

**Vas Narasimhan:** 所以我认为**早期干预**（early intervention: 在疾病早期阶段进行治疗或预防）是一个巨大的重点领域。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think early intervention is a is a huge area of focus.</p>
</details>

**Vas Narasimhan:** 另一个令人兴奋的领域显然是**疾病重置**（reset diseases: 通过干预机制使疾病状态逆转或恢复正常）的理念。这都源于细胞和基因疗法的世界，我们已经了解到，对于某些遗传性疾病，诺华是这方面的领导者之一。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think another exciting area clearly is the idea of can you completely reset diseases. This all comes out of the world of cell and gene therapies where we already learned that for certain genetic diseases and Novartis is one of the leaders here.</p>
</details>

**Vas Narasimhan:** 通过使用基因疗法实际替换体内的基因，我们几乎能够实现治愈或显著的反应。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">we're able to almost deliver a cure or a dramatic response by using the gene therapies to actually replace a gene in the body.</p>
</details>

**Vas Narasimhan:** 所以现在我们已经了解到，就在本周，有数据表明你可以实际使用细胞疗法来重置**免疫系统**（immune system: 身体抵抗疾病的防御系统）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So now what we've learned and there's actually data coming out just this week that you can actually use cell therapy to reset the immune system.</p>
</details>

**Vas Narasimhan:** 有一系列非常严重的免疫疾病影响着年轻人和老年人。这里的理念是，通过这些使用细胞疗法的治疗，你可以重置免疫系统，将疾病的时钟拨回15或20年。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And there's a whole range of imunological diseases that are very severe affecting young people and old people. And the idea here is with these therapies using cell therapy you can reset the immune system and turn back the clock on their disease by 15 or 20 years.</p>
</details>

**Vas Narasimhan:** 所以我认为这是一项惊人的创新，有望随着时间的推移改变数百万人的生活。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so this is I think a staggering innovation that will change the lives of you know hopefully over time millions and millions of people.</p>
</details>

**Vas Narasimhan:** 我非常兴奋的另一个领域是**RNA疗法**（RNA therapeutics: 利用RNA分子作为药物来调节基因表达或蛋白质功能的疗法），它允许你将通常每天服用的药物，只需每六个月或每年服用一次。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Another area I'm very excited about is an area called RNA therapeutics that allows you to give medicines that you usually take every day. You only need to take them every six months or maybe once a year.</p>
</details>

**Vas Narasimhan:** 大多数人不会服用他们的预防性他汀类药物或其他药物。所以如果我们能实现**不频繁给药疗法**（infrequently administered therapies: 药物给药频率较低，例如每几个月一次），那也将是非常令人兴奋的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And most people don't take their preventative statins or other medicines. So if we can get to infrequently uh administered therapies, that would be incredibly exciting as well.</p>
</details>

**Vas Narasimhan:** 如果您允许我，还有一个我认为非常令人兴奋的领域是**放射性药物**（radioarmaceuticals: 含有放射性同位素的药物）或放射配体疗法，诺华是这方面的先驱。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And if you'll indulge me, just one other I I think is super exciting is is radioarmaceuticals or radolyan therapy where Novartis is a pioneer here.</p>
</details>

**Vas Narasimhan:** 我们已经了解到，**放射线**（radiation: 能量以波或粒子形式传播）可以攻击**肿瘤**（tumors: 异常生长的细胞团），阻止肿瘤生长甚至消除肿瘤。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">What we've learned is we know radiation can can attack tumors and and stop tumors from growing or even eliminate tumors.</p>
</details>

**Vas Narasimhan:** 但现在我们可以利用与放射性粒子连接的药物，基本上将放射线微观地靶向到体内肿瘤所在的位置，这正在开辟一个全新的医学领域。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But now we can micro basically target radiation right to where the tumor is in the body using a drug linked to a radioactive particle and this is opening up a whole new area of medicine.</p>
</details>

**Vas Narasimhan:** 这些只是我们看到的一些例子。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So these are just some of the examples that we see.</p>
</details>

### 研发决策与AI驱动的药物发现

**Nicolai Tangan:** 嗯，这些是一些例子，但我的意思是，您个人如何保持对这些前沿的了解？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, so these are some of the examples but I mean how do you how do you personally stay on top of this?</p>
</details>

**Vas Narasimhan:** 我对此非常热情。我的意思是，正如我所说，我是一名医生科学家，我最喜欢的月度会议始终是我们的创新管理委员会会议，我担任主席已经13年了，从我担任开发主管到担任首席执行官的整个时期。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I'm quite passionate about it. I mean, as I said, I'm a physician scientist, and you know, my favorite meeting of of the month always is our innovation management board, which I've I've chaired now for 13 years since I was the head of development all through my time as CEO.</p>
</details>

**Vas Narasimhan:** 我阅读了所有这些文件，因为最终，我认为这就是像我们这样的公司必须交付的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh, I read every one of those documents because, you know, that that's in the end, I think, what a company like us has to deliver.</p>
</details>

**Nicolai Tangan:** 告诉我，告诉我关于那个会议的事。所以它是一次会议，这就像是公司的命脉会议吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Tell me tell me tell me about that meeting. So it's once is this is this like the is this like the the lifeblood meeting of the company?</p>
</details>

**Vas Narasimhan:** 我确实觉得它是公司的命脉会议。我们审查研究团队带入后期研究阶段的项目。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I do feel like it's the lifeblood meeting of the company. We review the projects that our research teams are bringing into later stages of research which are so how many I'm sorry.</p>
</details>

**Nicolai Tangan:** 抱歉，那么有多少人，会议中有多少人？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So how many how many people so so who who are in the meeting? How many people are you?</p>
</details>

**Vas Narasimhan:** 嗯，最终有很多与会者，但核心成员大约有七到八位领导者，包括研发主管、战略与增长主管、我们的商业领导者、我自己和首席财务官。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">H well there's a lot of people who end up attending but the core members is about seven seven leaders head of research development strategy and growth are commercial leaders and myself and the CFOs maybe eight people.</p>
</details>

**Nicolai Tangan:** 会议持续多久？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">how long does it last</p>
</details>

**Vas Narasimhan:** 有时是两次四小时会议，有时是一次六小时会议，但它确实是一个漫长的会议，不适合那些。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">sometimes it's two four hour meetings sometimes it's one six hour meeting uh but it is it is a long meeting it's not for the the</p>
</details>

**Nicolai Tangan:** 您主持吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">do you run it</p>
</details>

**Vas Narasimhan:** 是的，我主持。我主持这个会议已经很多年了，从开发时期到现在。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I do I I chair it and I I've chaired it now for uh a number of years from development times to to today.</p>
</details>

**Vas Narasimhan:** 当然，主持这样的会议实际上只是为了从会议室中的所有领导者那里获得最佳视角。我的意思是，与所有这些专家相比，我能知道什么呢？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But Of course, chairing a meeting like this is really just getting the best perspectives from all of the leaders in the room. I mean, what can I possibly know compared to all of these experts,</p>
</details>

**Vas Narasimhan:** 但我们总是让团队进来，我们的专家，无论是在癌症、心脏病还是研究专家或开发专家、科学家、医生。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">but we always have the teams come in, our experts, uh, in whether it's cancer or heart disease or research experts or development experts, scientists, physicians.</p>
</details>

**Vas Narasimhan:** 我认为我们做得更好的一件最重要的事情是进行辩论。我认为辩论是应对这些复杂话题并找到我们所说的这些奇迹的唯一途径。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh, and I think one of the most important things we've gotten much better at is having a debate. And I think debate is the only way you can navigate these complex topics and finding these these miracles that we talk about.</p>
</details>

**Vas Narasimhan:** 如果你不愿意在会议室中持有对立的立场，如果只是橡皮图章，那么你当然很容易陷入在医学和研发中做决策时出现的所有偏见。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">If you're not willing to have the counterveiling position in the room, if it's just rubber stamping, then of course you're liable to easily fall into all of the biases that come in to taking decisions in in medicine and R&D.</p>
</details>

**Nicolai Tangan:** 所以，V，我现在是您的顶级癌症研究员。好的。我来参加这个会议，您知道，我事先给了您200页的阅读材料，然后我来了，Nicolai Tangan，这位伟大的癌症专家。那么会发生什么？我进去，我做演示，还是您直接提问，或者会发生什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So V, I'm now your uh I'm now top uh cancer researcher. Okay. I come into this meeting uh you know on you know uh I've given you 200 pages to read beforehand and and here I come Nikolai Tangan the great cancer guy. So what happens I I come in there I do I present or you just go straight to questions or what what happens?</p>
</details>

**Vas Narasimhan:** 这些年来我们已经发展了这种模式。我们过去有很长的演示文稿。现在我们假设预读材料已经阅读完毕，我们要求负责人给我们一个三分钟的案例总结。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We've evolved this over the years. We used to have long presentations. Now we assume the pre-eread is read and we ask the person the the leader to give us you know just a three minute summary um of the case.</p>
</details>

**Vas Narasimhan:** 然后，我们通常还会放一张幻灯片，上面有团队认为做这个项目的原因或不做这个项目的原因。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then um we usually try to also put up a slide that has from the team's view what were the reasons to do the project or what were the reasons not to do the project.</p>
</details>

**Vas Narasimhan:** 我们还有一个投资组合分析小组，他们为我们提供了大量关于这些项目的数据和分析，然后我们进行讨论，我的职责是让会议室里的人真正讨论这个话题并进行辩论，看看我们是否通过资助这个项目到下一个阶段做出了正确的决定。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh we also have a portfolio analytics group that gives us lots of data and analyses on these projects and then we have a discussion and my role is to get that the room to really discuss the topic and have a debate and see uh are we doing the right thing by funding this project to the next tollgate.</p>
</details>

**Nicolai Tangan:** 如果您要终止一个项目，这会在这些会议中发生吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">and if you were to terminate uh a project does that happen in these meetings?</p>
</details>

**Vas Narasimhan:** 是的，我认为这是管理良好的研发组织必须做的最重要的事情之一。你必须在项目所处的位置上保持知识上的诚实。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yes, that and that is I think one of the most important things a well-run R&D organization has to do. You have to be intellectually honest as to where projects are.</p>
</details>

**Vas Narasimhan:** 它们是否符合你的战略？它们是否有数据支持继续进行？你必须有勇气，以友善但坚定的方式向团队解释我们必须在这里停止，我们必须将资源用于其他事情。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Do they fit in your strategy? Do they have the data to support going? Uh and you have to have the courage to kindly but firmly explain to teams that we have to stop here and we've got to use the resources for other things.</p>
</details>

**Vas Narasimhan:** 这显然从来都不容易，但我们总是努力赞扬团队，告诉他们不是团队失败了。如果他们工作得当，科学只是没有达到我们预期的效果。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">That's obviously never uh easy, but we always try to celebrate the teams and tell them it's not the teams that failed. If they did their work right, the science simply didn't deliver the way we expected.</p>
</details>

**Vas Narasimhan:** 这没关系。这只是我们工作的一部分。我们的大多数项目最终都会失败。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And that's okay. That's just part of the work that we do. most of our projects ultimately fail.</p>
</details>

**Nicolai Tangan:** 嗯，我不得不说，我真希望我能参加那个会议。那听起来比我们在基金的投资会议更有趣。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, I have to say I would have loved to sit in in that meeting. That sounds even more interesting than our investment meetings at uh in the fund, you know.</p>
</details>

**Vas Narasimhan:** 是的，我们的会议有时会有点艰难。所以，我想这就是我这些年来积累了一些会议耐力的地方。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, our six can get a little tough. So, that's uh that that's where I think I've built up some meeting endurance over the over the years.</p>
</details>

### AI与制药业的数字化转型

**Nicolai Tangan:** 接下来，人工智能和数字化，您确实是制药行业数字化转型的倡导者。您在一开始简要提到了其中一些数字计划，但您认为您拥有的最重要的数字计划是什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um moving on, um AI and digital, you've been you really have been a champion in the digital transformation in pharma. Now what um you mentioned briefly in the beginning some of the digital initiatives but what would you say are the most important ones that you have?</p>
</details>

**Vas Narasimhan:** 我认为人工智能在研发中的影响很可能对我们行业产生最长远的影响。在运营、制造、供应链、财务方面发生了很多事情。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I I think clearly AI's impact in research and development in our industry will likely have the longest lasting ex impact. There's a lot that's happening in operations manufacturing supply chain finance uh and that I think is is important clearly having an impact already but ultimately will become I think standard across our sector and other sectors.</p>
</details>

**Vas Narasimhan:** 这显然很重要，已经产生了影响，但最终我认为它将成为我们行业和其他行业的标准。这里最大的问题是，您能否使用人工智能来发现**药物靶点**（drug target: 药物作用于生物体以产生治疗效果的特定分子）？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The biggest question here is can you use AI um to either discover what is a drug target?</p>
</details>

**Vas Narasimhan:** 所以，把它想象成我们需要解锁的钥匙孔。找到那些钥匙孔，然后您能否也使用人工智能来优化钥匙进入钥匙孔，以便那把钥匙最终能够解锁我们正在谈论的生物过程。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So think of it as the key lock that we need to unlock. So find those key locks and then can you also use AI to optimize the key into the lock so that that key can ultimately unlock the biological process that we're talking about.</p>
</details>

**Vas Narasimhan:** 就我们今天所处的位置而言，我们已经与**同构实验室**（Isomorphic Labs: 谷歌DeepMind旗下的AI药物发现公司）、谷歌DeepMind（**Google DeepMind**: 谷歌旗下的人工智能研究公司）和其他合作伙伴一起使用人工智能来优化这些“钥匙”。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh now as to where we are today, we're already using AI with Isomorphic Labs, the Google Deep Mind Company, other partners to optimize those keys.</p>
</details>

**Vas Narasimhan:** 所以我们对这些“钥匙”有一些想法。人工智能获取所有已知信息，包括外部信息和公司内部信息，并优化这些候选药物，然后通过预测其在**临床前安全性毒理学**（pre-clinical safety toxicology: 在人体试验前评估药物毒性和安全性的研究）、**药代动力学**（pharmacokinetics: 研究药物在体内的吸收、分布、代谢和排泄过程）、**可制造性**（manufacturability: 产品设计和生产的难易程度）方面的最终表现，帮助我们加速这一过程。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">AI get takes all of the information known uh out there and inside the company and optimize those candidate drugs and then helps us speed up the process by predicting how it will ultimately do in pre-clinical safety toxicology uh in terms of its uh pharmacocinetics its manufacturability that process is now and that's really happening now at scale and companies like ours and at other companies uh and I think that will hopefully shorten the drug development early drug development process by years and that's I think really exciting.</p>
</details>

**Vas Narasimhan:** 这个过程现在正在我们公司和其他公司大规模发生，我认为这有望将早期药物开发过程缩短数年，这确实令人兴奋。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then the bigger question is could you actually unlock biological processes with AI and actually understand and that I'm think we're further away from.</p>
</details>

**Vas Narasimhan:** 然后更大的问题是，您能否真正用人工智能解锁生物过程并真正理解它们，我认为我们离这一点还很远。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I you work with Microsoft Palanteer but you mentioned the um isomorphic labs which is Habis's uh venture right you got the uh Nobel Prize um inside uh inside Google just how do you work with them what do they do for you</p>
</details>

**Nicolai Tangan:** 您与微软（Microsoft）和**Palantir**（Palantir: 一家大数据分析公司）合作，但您提到了同构实验室（Isomorphic Labs），这是哈比斯的风险投资，对吗？您在谷歌内部获得了诺贝尔奖，您是如何与他们合作的？他们为您做了什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I you work with Microsoft Palanteer but you mentioned the um isomorphic labs which is Habis's uh venture right you got the uh Nobel Prize um inside uh inside Google just how do you work with them what do they do for you</p>
</details>

**Vas Narasimhan:** 是的，我认为我们是他们仅有的两个合作伙伴之一。基本上，我们所做的是，再次以钥匙孔和钥匙的比喻来说，我们给他们一些我们知道或假设在癌症或心脏病等疾病中非常重要的“钥匙孔”，而我们却一直无法“成药”，即找不到“钥匙”。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">yeah so it's a it's a very I think we're one of their two partners and basically ally what we do is we give them again to take the the key the key lock and the key analogy we give them some locks that we know or we hypothesize are very important in diseases like cancer or heart disease that we simply have not been able to drug or i.e find the key for.</p>
</details>

**Vas Narasimhan:** 我们说，我们用传统方法遇到了困难，人工智能及其能力能否最终使我们找到这些“钥匙”？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And we say we've struggled with our traditional methods can AI can their capabilities uh ultimately enable us to to find those keys.</p>
</details>

**Vas Narasimhan:** 所以他们所做的是利用人工智能设计新药。非常有趣的是，人工智能提出了我们从未考虑过或真正探索过的药物结构。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so what they do is they use AI to design new drugs and what's been very interesting is they come AI comes up with drug structures that you know we've not thought about or really explored um and so we're starting to see the early results.</p>
</details>

**Vas Narasimhan:** 我认为我们现在与他们有超过六个不同的项目正在进行中，并希望未来能进一步扩展。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think we now have over six different projects going with them and hopefully to expand more into the future.</p>
</details>

**Vas Narasimhan:** 如果人工智能能解决我们所谓的**不可成药靶点**（undruggable targets: 那些目前没有有效药物可以作用的生物靶点）。所以，人工智能能否帮助我们“成药”那些不可成药的靶点？这就是问题所在。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And we'll If AI can solve what we call our undruggable targets. So, can the AI help us drug the undruggable? That's the question.</p>
</details>

**Nicolai Tangan:** 有趣的是，与科技公司的关系已成为制药业成功的关键，对吗？因为在过去并非如此。您认为这种关系未来会如何变化？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's interesting how relationships with uh technology companies has been key to success in pharma, right? Because that wasn't the case in the old days. H how how do you see this changing going forward?</p>
</details>

**Vas Narasimhan:** 这是一次巨大的转变。我的意思是，我认为这些年来我们已经学到了很多。Palantir一直是我们的出色合作伙伴。我们从2017年开始与他们合作。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Just it's a big shift. I mean, I think you know, we've learned over the years. Palanteer has been an amazing partner of ours. We've been working with them since 20 2017.</p>
</details>

**Vas Narasimhan:** 他们帮助我们建立了一个名为“数据42”的数据湖，我们认为这是行业中最先进的数据湖之一。它帮助我们仅使用一个简单的文本字段就能挖掘所有数据。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">They've helped to build a data lake we call data 42 which we think is one of the most advanced in the industry. Helps us mine all of our data just using a simple text field.</p>
</details>

**Vas Narasimhan:** 微软研究院（**Microsoft Research Labs**: 微软的全球研究部门）一直是一个伟大的合作伙伴。我认为关键在于，你必须找到正确的用例。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Microsoft Research Labs has been a great partner. I think what it is is, you know, you have to find the right use cases.</p>
</details>

**Vas Narasimhan:** 很容易尝试追逐各种事物，我们也曾陷入那个陷阱。我们追逐了太多的人工智能和数据科学项目。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's easy to try to chase all kinds of things and we fell into that trap. We chased far too many AI and data science projects.</p>
</details>

**Vas Narasimhan:** 但正如我们这些年所学到的，如果你找到正确的用例并找到正确的合作伙伴，我的意思是，亚马逊（**Amazon**: 跨国科技公司）也帮助我们完全自动化了在美国的患者服务，作为另一个例子，你需要这些合作伙伴关系，因为我们内部根本不具备这些技术知识。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But as we've learned over the years, if you get the right use cases and you find the right partners, I mean, Amazon has helped us completely automate our patient services in the United States as another example, you need those partnerships because we simply don't have the technological know-how in house.</p>
</details>

**Nicolai Tangan:** 您认为您比竞争对手更擅长与科技公司合作吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Do you think you're better at working with the tech companies than your competitors?</p>
</details>

**Vas Narasimhan:** 我不知道。你得去问那些科技公司。我的意思是，我确实认为，诺华的一大优点是，我们愿意在最前沿进行开拓。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I don't know. You'd have to ask the the the tech companies. I mean, I do think, you know, one of the great things about Novartis is we're willing to pioneer at the cutting edge.</p>
</details>

**Vas Narasimhan:** 我的意思是，如果你看看我们行业中的许多技术领域，无论是治疗平台、人工智能还是数据科学，我们总是走在前沿。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, if you look at a lot of the technology areas in our industry, whether it's therapeutic platforms, AI, data science, we're always at the leading edge.</p>
</details>

**Vas Narasimhan:** 这也意味着我们经常不得不克服许多早期挑战，也常常意味着我们会遇到相关的失败，但这就是我们公司的精神。我们走在前沿。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">That also means we often have to fight through many of the early challenges and often means also we have the failures associated with that, but that's kind of the ethos of our company. We're at the leading edge.</p>
</details>

### 欧洲制药业的挑战与政策建议

**Nicolai Tangan:** 您一直对欧洲制药业面临的挑战直言不讳。我曾听您在一次会议上发言，当时我就想“哇，这个人真的很直言不讳，他告诉我们他真正的想法”，而许多首席执行官实际上不会这样做。那么，请告诉我们欧洲制药业的现状，毫不含糊地。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You've been uh very outspoken about the challenges facing the European pharma industry. And I I I heard you for instance in divorce and I was just like wow this guy is actually he's he's pretty outspoken you know he's like he's telling us what he really thinks and and there are many cos who actually don't do that. So so tell us about this tell us about the situation of pharma in Europe in kind of no uncertain terms and and that I I've pretty consistently done uh to to also directly to the senior leaders.</p>
</details>

**Vas Narasimhan:** 我一直都非常坚持这一点，也直接向高级领导人表达。欧洲一直是制药业的故乡。我的意思是，如果你回顾100年前，最早的制药公司都沿着莱茵河及其相关地区发展起来，那里是这个行业最终诞生的地方。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You know, Europe has been the the home of the pharmaceutical industry. I mean, when you look at it 100 years ago, the earliest pharmaceutical companies all came up along the Ryan River and in related parts of of Europe, it's where the industry ultimately was created.</p>
</details>

**Vas Narasimhan:** 在过去的一个世纪里，它仍然是世界真正的动力源。如果你看看现在大多数药物的生产地，是在欧洲，许多研发活动也在欧洲进行。临床试验也在欧洲进行。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And over the last century, it still has been the real powerhouse of the world. When you look at where drugs are most most manufactured right now, uh it's in it's in Europe where a lot of R&D activity is happening in Europe. Clinical trials is happening in Europe.</p>
</details>

**Vas Narasimhan:** 但与此同时，欧洲各国政府却将我们提供的创新商品化，并且越来越多地通过预算限制来限制他们如何奖励创新，通过人为抬高价格来扶持仿制药行业，而不去解决医院部门的问题。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But at at the same time what's happened is European governments have just commoditized the innovation that that we deliver and more and more through budget uh constraints constraining how they uh reward innovation propping up the generics industry with artificially elevated prices not taking on the hospital sector.</p>
</details>

**Vas Narasimhan:** 他们不断施加限制，以至于现在欧洲的人口略多于美国，但其市场规模只有美国的一半甚至更少，而且没有增长，而美国和现在的中国，我的意思是，中国是世界第二大制药市场，增长率接近20%或至少两位数。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">they've constrained and constrained to the point now where Europe at population slightly larger than the United States its market size is half or even less than half of of the US and not growing whereas the US and now China I mean China is the second largest pharmaceutical market in the world growing almost at 20 or growing certainly double digit.</p>
</details>

**Vas Narasimhan:** 所以欧洲需要做些什么，因为显然，美国政府希望制造业转移，我们已经看到公司宣布了2500亿美元的投资，表示他们将更多地投资美国，欧洲公司也表示他们将更多地投资美国。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so Europe needs to do something because clearly you know the US administration wants manufacturing to move we've seen $250 billion of announcements from companies saying they're going to invest more US and European companies saying they're going to invest more in the US.</p>
</details>

**Vas Narasimhan:** 所以欧洲必须采取行动，他们必须找出如何奖励创新，而不是限制药品价格，惩罚拥有新技术和新创新的公司，而不是人为地寻找方法来真正限制创新环境，否则它将随着时间的推移而流失。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So Europe has to act they have to figure out how to reward innovation by not capping drug prices, penalizing companies when they have new technologies and new uh innovations, not artificially finding ways to really constrain the innovation environment or it it will over time leave.</p>
</details>

**Vas Narasimhan:** 我的意思是，这只是经济学问题。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, it's just the economics.</p>
</details>

**Nicolai Tangan:** 欧洲行动不够快吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">is Europe acting not fast enough.</p>
</details>

**Vas Narasimhan:** 不，我的意思是，我认为欧洲正在欧洲层面尽其所能，但我认为真正的艰难对话仍需进行，而且我认为贸易局势肯定会进一步推动这个话题，正如特朗普政府对国际参考定价的推动一样。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">No, I mean I think Europe is trying at the European level to do what they what they can uh easily, but I think the real hard conversations still have to happen and I think certainly the the trade situation will push that topic even even harder as will the Trump administration's push on international reference pricing.</p>
</details>

**Nicolai Tangan:** 但是什么阻碍了欧洲的行动？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">What's but what's what's preventing Europe from moving?</p>
</details>

**Vas Narasimhan:** 这是一个好问题。我的意思是，我认为最终是政治意愿，以及一种根本性的信念，认为这个行业不会转移，或者它不会导致转变。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">That's a good question. Right. I mean I think it's political will um ultimately and and a fundamentally a belief that the industry won't move or or it won't lead to a shift.</p>
</details>

**Vas Narasimhan:** 正如你所知，这些转变不会迅速发生，而是随着时间的推移缓慢发生。十年后，你就会开始说，现在大约有40%的新药，30%到40%的新药没有在欧洲上市。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And as you know I mean these shifts don't happen like you know rapidly but slowly over time in 10 years from now you start to say today about 40% of new drugs 30 to 40% of new drugs are not launched in Europe.</p>
</details>

**Vas Narasimhan:** 欧洲患者无法获得它们。它们主要在美国、一定程度上在中国和日本上市。这个数字会慢慢增加。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">European patients don't get access to them. They're primarily launched in the US to some extent China and Japan. That number will slowly increase.</p>
</details>

**Vas Narasimhan:** 缓慢但肯定地，你会看到制造业离开。诺华在英国有四家制造工厂。今天我们一家都没有。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Slowly but surely you'll see manufacturing leave. Novartis had four manufacturing plants in the UK. We have zero today.</p>
</details>

**Vas Narasimhan:** 一步一步地，你会看到，然后突然间，我认为它会不幸地演变成一场危机，就像在日本制药行业发生的那样，然后政府就会采取行动，因为患者会要求这些药物在哪里。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh step by step you'll see and then suddenly I think it'll get to a unfortunately to a crisis as it did in Japan for the pharmaceutical sector and then governments will act because patients will demand where are these medicines.</p>
</details>

**Vas Narasimhan:** 政府会关注就业机会的流失。但不幸的是，我认为在我们达到那个危机点之前，很容易就希望现状足够好。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Governments will be looking at where do the jobs go. But unfortunately I think until we get to that crisis point it's easy just to hope that the status quo will be good enough.</p>
</details>

**Nicolai Tangan:** 问题出在布鲁塞尔还是各个国家？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Is the problem uh Brussels or is it the individual countries?</p>
</details>

**Vas Narasimhan:** 我的意思是，我认为挑战当然是布鲁塞尔会说他们不控制创新生态系统和个体市场。所以各个国家必须做出自己的决定。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean I think I think that the challenge of course Brussels would say they don't control innovation ecosystems and individual markets. Um and so individual countries have to make their own decisions.</p>
</details>

**Vas Narasimhan:** 话虽如此，我认为在一个拥有27个成员国的联盟中，如果没有某种协调行动，考虑到贸易最终是在欧盟层面管理的，要解决这个问题将非常困难，因为欧盟各国人均GDP存在差异。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">uh that said I think with a 27 member block without some sort of coordinated action given the trade is ultimately managed at the EU level it's going to be very difficult to tackle this problem because of the just this the dispar the differences in uh GDP per capita across the European Union.</p>
</details>

**Vas Narasimhan:** 所以我认为布鲁塞尔需要提出一个框架来指导各国，否则我们将无法摆脱这种局面。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so I think Brussels needs to come up with a framework to guide the countries otherwise we won't get out of the situation.</p>
</details>

**Nicolai Tangan:** 各国需要做些什么才能更多地考虑欧洲的共同命运，而不是仅仅考虑自己的情况？因为这不仅在制药行业，我们几乎在每个行业都看到了这种情况，对吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">what would what would it take for the countries to think more about the uh common destiny of Europe rather than just their on situation because it's not only in the farmer industry we seeing this right we're seeing it in pretty much every industry.</p>
</details>

**Vas Narasimhan:** 是的，确实如此，当然，我认为各国政府会说他们必须解决国防问题，他们必须解决能源问题，他们必须解决制药行业的问题。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">it's true and it's not and of course I think governments would say they've got to figure out defense they've got to figure out energy they've got figure out the pharmaceutical sector.</p>
</details>

**Vas Narasimhan:** 我的意思是，我认为最终需要领导力，而且，我认为一些欧洲领导人必须激发整个欧洲的支持，而且我认为这当然具有挑战性，但你需要一些欧洲的高级领导人站出来说他们将承担起这个责任。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean I think it's going to take ultimately leadership and uh you know I think some more of the European leaders have to galvanize support across Europe uh and I think that of course that's challenging but you need I think some senior leaders in Europe to say they're going to take this on.</p>
</details>

**Vas Narasimhan:** 我认为如果每个国家都固守自己的角落，并希望这会自行解决，那么我认为故事将继续以目前的方式展开。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think if each country sits in their corner and kind of hopes that this will work itself out, I think the the story will keep unfolding the way it's unfolding.</p>
</details>

**Nicolai Tangan:** 嗯，德拉吉（**Draghi**: 欧洲央行前行长，曾撰写关于欧洲竞争力的报告）写了这份报告，但我想没有发生太多事情。尽管世界正在变化，关税和壁垒等等都在移动，您对这份报告发布后没有发生更多事情感到惊讶吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, I mean, Draghi wrote the report, but uh I guess not so much is happening. Um despite um the despite the world changing, right, with uh tariffs and barriers and so on uh moving, are you are you surprised that not more is happening after this report?</p>
</details>

**Vas Narasimhan:** 我的意思是，我认为至少有了一些认识，我不得不说，至少欧盟委员会的基调更多地关注经济竞争力，而不是，你知道，我们曾经有那么多新的官僚主义元素被添加进来，无论是**CSRD**（Corporate Sustainability Reporting Directive: 企业可持续发展报告指令）、**尽职调查**（due diligence: 在交易或决策前对相关事项进行调查和评估）还是水资源管理（water: 此处指水资源相关的法规或政策），所有这些都层层叠加。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean I think there was at least recognition and I I have to say that at at least the tone uh from the European Commission is much more about economic competitiveness and less about uh you know the whole period of time where we had so many new bureaucratic elements being added whether it was CSRD or uh the due diligence or water and all of these things added on top of each other.</p>
</details>

**Vas Narasimhan:** 话虽如此，我认为行动一直很缓慢。我认为，虽然言论很高调，但最终公司会根据他们看到的实际具体行动做出反应。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um that said I think action has been been slow. Uh I think uh and I think while the talk has been you know high ultimately companies respond to when they see real concrete action.</p>
</details>

**Vas Narasimhan:** 欧盟确实提出了新的制药立法提案，这在一定程度上改善了他们已经非常具有破坏性的保护药品数据的方法。但即使如此，这仍然比我们三年前的情况更糟。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh the EU did put out new pharmaceutical proposed pharmaceutical legislation which improves somewhat from their already really damaging approach to protecting pharmaceutical data. But already that's still worse than where we were 3 years ago.</p>
</details>

**Vas Narasimhan:** 所以我们实际上是从一个变得更糟的地方，现在变得不那么糟了，然后这就被认为是胜利。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So we actually went from a place where we got much worse and now we're less worse and then that's supposed to be a victory.</p>
</details>

**Vas Narasimhan:** 所以，我认为必须有更强的紧迫感。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um so you know I I think there has to be more of a sense of urgency.</p>
</details>

**Nicolai Tangan:** 那么，Vas，我给您这根魔杖。您可以改变欧洲制药业的三件事。您会改变什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So Vas, I'm giving you this magic wand. You can change three things in European farmer. What would you change?</p>
</details>

**Vas Narasimhan:** 我会说我们应该有一个**全欧洲统一标价系统**（Europeanwide list price system: 在整个欧洲范围内统一制定药物的标示价格），然后各国可以根据人均GDP进行调整，这为我们在整个欧洲的标价提供了一个框架。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I would say the that we should have uh Europeanwide uh list price system that then countries can adjust based on GDP per capita that then gives us a framework for list prices across Europe.</p>
</details>

**Vas Narasimhan:** 其次，我认为不应该允许**限制制药行业的增长**（capping growth: 对行业或公司的增长设定上限）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh I think second there should be no allow allowance for capping growth of the pharmaceutical sector.</p>
</details>

**Vas Narasimhan:** 所以基本上，如果你以意大利为例，我们在意大利的全部增长在年底都会返还给意大利。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So basically like if you take a country like Italy, our entire growth in Italy is paid back to Italy at the end of the year.</p>
</details>

**Vas Narasimhan:** 所以如果你总是把你的增长返还给国家，就很难发展业务。许多国家都有这种情况。所以我们必须结束这种做法。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh and so it's very hard to to grow a business if you're always paying back your growth to the to the c many countries have this. So we've got to end this end this practice.</p>
</details>

**Vas Narasimhan:** 第三，我认为欧洲也必须结束扶持**仿制药行业**（generics industry: 生产非专利药物的行业）的做法。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um and then and then third I think uh Europe has to end also its practice of propping up the generics industry.</p>
</details>

**Vas Narasimhan:** 转向**美国模式**（US model: 指美国在制药行业的市场化运作模式），在那里我们有高创新，然后仿制药价格是世界上最低的。然后你就会找到财政空间来投资创新。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh go to the US model where we have high innovation and then generics prices that are the lowest in the world. Uh and then you'll find the fiscal space to invest in innovation.</p>
</details>

**Vas Narasimhan:** 我认为这三项改变都是非常可行的。我们在《金融时报》（**Financial Times**: 英国知名的商业财经报纸）上写过这篇文章。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">These are three I think very doable uh changes. We tal wrote about it in the financial times.</p>
</details>

### 地缘政治与中国生物技术生态系统

**Nicolai Tangan:** 那么新的**地缘政治局势**（geopolitical situation: 国际政治和经济力量的地理分布及其影响）如何影响您的思考方式？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">and let's see how does the new geopolitical situation impact the way you think.</p>
</details>

**Vas Narasimhan:** 嗯，我认为首先我告诉我的员工的是，我们已经存在了250年。我们必须专注于我们可控的方面，专注于寻找下一波药物，好好地推出它们并做好我们的工作。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, I think first what I tell my people is we've been around for 250 years. We have to focus on our controllables, focus on our finding the next wave of medicines, launching them well and doing our work.</p>
</details>

**Vas Narasimhan:** 这就是诺华的精力必须投入的地方。现在，我认为关于我们如何适应当前局势，最重要的是要有更大的灵活性。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">That's where the energy of Novartis has to go. Now, I think on how we adjust uh to the current situation, I think the most important thing is to have more flexibility.</p>
</details>

**Vas Narasimhan:** 我们决定做的是确保我们在美国拥有针对美国的**生产能力**（manufacturing capacity: 生产产品或服务的最大能力），这样我们就可以在美国为美国生产我们最重要的药物，为欧洲生产，然后类似地在中国拥有生产能力，这样就可以使我们的供应链更加灵活。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And what we've decided to do is ensure we have manufacturing capacity in the US for the US so that we can manufacture our most important medicines for the US in the US for Europe and then similarly have manufacturing in China so that flexibilizes our our supply chain.</p>
</details>

**Vas Narasimhan:** 我们还在努力使我们的研发**临床试验招募**（clinical trial recruitment: 招募符合条件的患者参与临床试验的过程）能力更加灵活，这样我们显然可以适应。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We're also working to flexibilize our R&D clinical trial ability so we can obviously adapt.</p>
</details>

**Vas Narasimhan:** 所以我认为你必须在公司内部创建更具适应性的系统，以及更强的能力来应对政策的变化。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think you have to create much more adaptable systems in your company and much more ability to react to how how the policies uh change.</p>
</details>

**Nicolai Tangan:** 谈到中国，您曾称中国的创新生态系统是行业的一个“警钟”，您还谈到中国临床试验招募的惊人速度。请告诉我们，他们是如何做到的？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">When it comes to China, you have you've called the Chinese innovation ecosystem a wakeup call for the industry and you also talk about staggering pace of clinical trial recruitment in China. Just um tell us what um why are they getting it right there?</p>
</details>

**Vas Narasimhan:** 嗯，你知道，中国的故事很有趣。如果你回到2014年，中国在生物制药领域并不是一个强劲的参与者。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, you know, China the story is interesting. And when you go back to 2014, uh, China was not a power player in in biioharmaceuticals.</p>
</details>

**Vas Narasimhan:** 首先，他们在**政策和监管框架**（policy and regulatory framework: 规范行业或活动的法律、法规和指导方针）方面做了一些重要的改变。他们使药品监管机构现代化，并提高了所有制造商的质量标准，这在一定程度上淘汰了许多低于适当标准的本地参与者。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">First, they made some important uh changes in their policy and regulatory framework. They modernized their drug regulator and increased the quality standards for all manufacturers which kind of eliminated a lot of the local players who were below uh appropriate standards.</p>
</details>

**Vas Narasimhan:** 他们创建了一个名为**NRDL列表**（NRDL list: 国家基本医疗保险、工伤保险和生育保险药品目录）的**国家报销系统**（national reimbursement system: 由国家层面管理的医疗费用报销制度）用于新药。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">They created a national reimbursement system called the NRDL list for new medicines.</p>
</details>

**Vas Narasimhan:** 但后来他们还决定创建一个名为**基于价值的定价**（value-based pricing, VBP: 根据药物为患者带来的价值来确定价格的机制）的流程，当药物生命周期结束时，它们变得极其便宜。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But then they also decided to create a process called valuebased pricing VBP that when drugs are at the end of their life cycle they become extremely cheap.</p>
</details>

**Vas Narasimhan:** 他们将所有这些整合到一个方案中，然后一步步地开始加快他们的**药品监管机构**（drug regulator: 负责审批和监管药品上市的政府机构）的审批速度，加快他们的临床试验。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">They put all of this together into a package and then step by step they began to speed up their regulator speed up their clinical trials.</p>
</details>

**Vas Narasimhan:** 大约五六年前曾有过一次大爆发，但最终并未成功，当然，随后出现了收缩，然后正如你所知，现在这个行业又非常强劲地回来了。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Now there was a big boom five six years ago uh and then ultimately uh it didn't pan out and of course there was then retrenchment and then as often is the case as you know uh now the sectors come back very strong.</p>
</details>

**Vas Narasimhan:** 我们看到最大的转变是：第一，我们不再仅仅看到“快速跟随者”，我们实际上看到了**创新药物**（novel innovation: 指全新的、具有突破性治疗效果的药物）和新的药物靶点、新技术。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And what we see the biggest shifts are one u we're no longer seeing fast follower alone we're actually seeing novel innovation novel drug targets novel technologies.</p>
</details>

**Vas Narasimhan:** 第二，中国临床试验的启动和招募速度现在是世界上最快的，它肯定超过了欧洲，也超过了美国。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Two the pace of clinical trial uh start and recruitment in China is now the fastest in the world it's outpacing eur Europe certainly outpacing um the US.</p>
</details>

**Vas Narasimhan:** 第三，药品监管机构的速度加快了。所以你现在在中国获得批准的速度几乎与在美国获得批准的速度一样快。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Three, the drug regulator has sped up. So you can get approvals now in China almost at the same speed as you get um in the US.</p>
</details>

**Vas Narasimhan:** 我认为也有资本流入上海生物技术产业（**Shanghai biotech sector**: 上海的生物技术产业集群），这创造了大量的公司。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And I think there's capital as well flowing into the Shanghai biotech uh se uh sector and that's creating you know a lot of company formation.</p>
</details>

**Vas Narasimhan:** 所以我认为这导致了近年来首次有多个源自中国的创新药物在美国获得批准，而且这种速度还在继续。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So this has led I think now to the for the first time multiple new drugs in recent years novel drugs originating from China getting approved in the US and the pace of that is only continuing.</p>
</details>

**Vas Narasimhan:** 所以我认为所有大型生物制药公司现在都在关注上海，与波士顿（**Boston**: 美国重要的生物技术中心）和圣地亚哥（**San Diego**: 美国重要的生物技术中心）以及其他一些中心并驾齐驱。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think all big bioarma now is looking to Shanghai um alongside Boston and San Diego and some of the other hubs.</p>
</details>

**Nicolai Tangan:** 美国和中国是否存在停止接受彼此临床数据的风险？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Is there a risk that US and China will stop accepting each other's clinical data?</p>
</details>

**Vas Narasimhan:** 存在风险。我认为这将是非常具有破坏性的。我的意思是，目前的整个生态系统都建立在全球临床试验的基础上。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">There's a risk. I think it would be very damaging. I mean the whole ecosystem at the moment is built around the fact that we run global clinical trials.</p>
</details>

**Vas Narasimhan:** 我的意思是，美国通常占大多数临床试验招募的30%左右。显然，中国现在占据的比例越来越大。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean the US is usually about 30% of most clinical trial recruitment. Uh clearly China now makes up an increasing proportion.</p>
</details>

**Vas Narasimhan:** 如果你将临床试验的世界**分裂**（vulcanize: 使分裂成许多小部分）开来，这将对生物制药创新造成巨大损害。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">If you were to bulcanize the world of clinical clinical trials, this would be hugely damaging for bio biioharmaceutical innovation.</p>
</details>

**Vas Narasimhan:** 我的意思是，你将显著推迟药物上市时间，仅仅因为你无法在美国完全招募到足够的患者。欧洲也放慢了速度。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, you will set back drug timelines significantly simply because you just can't fully recruit in the US. Europe is also slowed down.</p>
</details>

**Vas Narasimhan:** 所以，我们需要亚洲以适当的速度完成我们的试验招募。而且，如果你从效率的角度考虑，我们可以在大约相同的时间获得两个市场的批准。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, we need Asia to kind of complete our trial recruitment at the appropriate pace. And also, if you think about it from an efficiency standpoint, we can get approvals in both markets around the same time.</p>
</details>

**Vas Narasimhan:** 所以，这当然会增加我们的回报率。否则，你知道，你会在不同地理区域之间看到巨大的时间差异。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, that of course increases our return profile. Otherwise, you know, you're going to have big discrepancies in timelines between the geography.</p>
</details>

### 全球健康承诺与领导力哲学

**Nicolai Tangan:** 我们在这里谈到了定价，但诺华在**药品可及性指数**（Access to Medicines Index: 衡量制药公司在低收入和中等收入国家药品可及性方面表现的指数）中排名第一。请告诉我们您对全球健康的承诺。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We we touched on on on pricing here, but um Novartis is ranked number one in in the access to medicines index. Um tell us about your your commitment to global health generally.</p>
</details>

**Vas Narasimhan:** 是的。我的意思是，你看，我最初是一名全球健康医生，个人对这方面充满热情。正如您提到的，我曾致力于疟疾、肺结核、艾滋病毒/艾滋病（**HIV/AIDS**: 人类免疫缺陷病毒和获得性免疫缺陷综合征）的防治工作。所以，这是我的一个热情项目。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah. I mean, look, I started as a as a global health uh physician deeply passionate about, you know, that personally. I've worked on as you mentioned malaria, TB, HIV, AIDS. So, that's a passion project of mine.</p>
</details>

**Vas Narasimhan:** 现在，我们之所以被视为药品可及性方面的领导者，是因为我们不仅在**热带疾病**（tropical diseases: 主要在热带和亚热带地区流行的疾病）方面提供帮助，例如疟疾、麻风病（**leprosy**: 一种慢性传染病）及相关疾病，而且我们在七八年前就将其列为优先事项，承诺在低收入国家尽快提供我们最新的创新成果，就像我们在高收入国家提供一样。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Now the reason you know we're really I think viewed as a leader in access is we not only provide access to our efforts in tropical diseases where malaria leprosy and related conditions we made it a priority uh you know seven eight years ago to say we want to provide access to our latest innovations as fast as possible in low-income countries to when we provide access in high-income countries.</p>
</details>

**Vas Narasimhan:** 我们通过各种不同的机制来实现这一点，例如新兴市场品牌和其他方法，希望能将这些药物带给越来越多的患者，这使我们能够比许多同行拥有更广泛的影响力，我对此感到非常自豪。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We do that through a variety of different mechanisms, emerging market brands, uh other approaches that that hopefully get these medicines to more and more patients and that allows us to have much more reach perhaps than many of our of our peers and I take great pride in that.</p>
</details>

**Vas Narasimhan:** 所以你可以在世界任何地方获得诺华的血液病药物、心力衰竭药物或免疫学药物，我们制定了可及性计划，以确保在许多这些疾病中没有患者被遗弃。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So you can get a Novartist uh hematology medicine or heart failure medicine or immunology medicine uh anywhere in the world and we we figure out access programs so that no patient gets left behind in many of these diseases.</p>
</details>

**Nicolai Tangan:** 谈到领导力。您工作中最好玩的部分是什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Moving on to leadership. Um, what's the most fun part of your job?</p>
</details>

**Vas Narasimhan:** 我认为与世界各地的人们互动。我的意思是，我想到今年，我已经去过日本、中国，去过欧洲各地，在美国，与我们的人互动。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think interacting with people around the world. I mean, I think about this year, I've already been, you know, I've been in Japan, I've been in China, um, I've been all across Europe, in the in the US, and interacting with our people.</p>
</details>

**Vas Narasimhan:** 这是一个演变。我的意思是，我想我早些时候会说，我热爱科学，我工作中最好玩的部分是创新管理委员会会议，以及参与所有科学决策。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And that's an evolution. I mean, I would have said, I think earlier on in my time, I love the science and the most fun part of my job is that IMB meeting and being involved in all the scientific decisions.</p>
</details>

**Vas Narasimhan:** 但是，你知道，现在我已经是第八年了，我意识到这个角色很大一部分是为人们提供能量。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But, you know, now that I'm in year eight, I realize so much of this role is providing energy to the people.</p>
</details>

**Vas Narasimhan:** 我的意思是，你是首席能量官，你必须给予能量。你必须建立信念。而这最终是通过人际互动实现的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You have to I mean, you're the chief energy officer and you have to give energy. You have to build belief. Um, and that comes through human interaction in the end.</p>
</details>

**Vas Narasimhan:** 这才是真正推动公司应对我们所面临的所有挑战的力量。所以，这绝对是给我最多能量的。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh, and that's what really powers a company to navigate all of the challenges that that we have. Uh, so that that's definitely what gives me the most energy.</p>
</details>

**Nicolai Tangan:** 您一直都是首席能量官吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Have you always been the energy officer?</p>
</details>

**Vas Narasimhan:** 不，我不这么认为。我学到了很多。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">No, I don't think so. I've learned I've learned so much.</p>
</details>

**Nicolai Tangan:** 您是如何学习成为一名能量官的？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You know, how do you learn how do you learn to How do you learn to be an energy officer?</p>
</details>

**Vas Narasimhan:** 我有很棒的教练。我认为我必须真正反思这个角色的意义。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You know, I've I've I've had great coaches. I've had to I think um really reflect on what does the role mean?</p>
</details>

**Vas Narasimhan:** 我的意思是，给予能量很大一部分是拥有能量。所以，你知道，我围绕**心态、运动、营养和恢复**（mindset, movement, nutrition, recovery: 个人健康和表现的四个关键支柱）制定了全面的方法，以确保我每天都能充满活力地出现。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, so much of giving energy is having energy. So, I you know, whole approach around mindset, movement, nutrition, recovery for myself to make sure I can show up every day um with energy.</p>
</details>

**Vas Narasimhan:** 但我也认为，关键在于当你意识到领导力实际上是关于你为你的团队和身边的人创造的可能性时。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But I also think the unlock is when you realize that leadership is really about the possibilities you create for your teams and the people around you.</p>
</details>

**Vas Narasimhan:** 领导力不是关于组织结构图。它不是关于等级制度。它是关于你创造的可能性。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Leadership is not about the org chart. It's not about the hierarchies. It's about the possibilities that you create.</p>
</details>

**Vas Narasimhan:** 如果你做出了这种思维上的飞跃，你就会意识到这一切都与你付出的能量、你创造的可能性有关。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And if you make that mental jump, then you realize it's all about the energy you give, possibilities you can create.</p>
</details>

**Vas Narasimhan:** 然后它当然会成为一个自我实现的循环。你感受到能量，你付出能量。我认为这无疑是我领导力旅程中的一个巨大飞跃。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, and then it becomes of course a, you know, self self-fulfilling cycle. You feel the energy, you give the energy. Um, and I think that was a certainly a big jump for me over my leadership journey.</p>
</details>

**Nicolai Tangan:** 您是否有某个特定的时刻让您对此更加清晰？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Did you have a particular moment where it became clearer to you?</p>
</details>

**Vas Narasimhan:** 是的，我的意思是，我不知道是否有某个特定的时刻，但肯定有一些时刻，我认为我旧的领导模式不起作用。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, I mean I think I don't know if there was a particular moment, but there were definitely moments where I think my old leadership model was not working.</p>
</details>

**Vas Narasimhan:** 我的意思是，我一开始是一个非常技术化、非常聪明、有点自以为是的领导者。你总会遇到瓶颈，尤其是在面对销售团队时，你必须激励和鼓舞一个团队，他们必须走进医生办公室，基本上被拒绝10次，然后希望能得到一次肯定。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, I started out as a very technical, very intelligent kind of know-it-all leader. There was a point you hit a wall, especially when you're in front of sales forces and you have to inspire and motivate a team that has to walk into a doctor's office and get, you know, basically told no 10 times uh and then hopefully get the one yes.</p>
</details>

**Vas Narasimhan:** 这需要不同的领导力，不同的方法。我领导过研发组织，你必须激励人们克服失败。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Different leadership, different approach. and I led R&D organizations where you have to get people to motivate through failure.</p>
</details>

**Vas Narasimhan:** 每六、七、八个项目只有一个成功，你必须激励人们度过这个过程。所以我想，通过每一次这样的经历，我都进行了调整，并努力学习如何更好地领导。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Only one out of six, seven, eight projects succeed and uh you got to motivate people through that. So I think with each one of these experiences I've adapted and tried to learn how to lead lead better.</p>
</details>

**Vas Narasimhan:** 我总是把自己看作是领导力的学生。我的意思是，你如何不断努力，变得更好？领导力旅程没有终点，但你必须不断问自己如何调整并在这方面做得更好。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think of myself as a always as being a student of leadership. I mean how do you keep working on it getting better? There's no destination on that leadership journey, but you have to keep asking yourself how can you adjust and get better at at this.</p>
</details>

**Nicolai Tangan:** 但我的意思是，您是从一个书呆子般的内向者转变为今天的外向者吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But I mean, did you transform from like a nerdy introvert to to the extrovert you are today or</p>
</details>

**Vas Narasimhan:** 我想我内心深处可能仍然是一个书呆子般的内向者。我可能会。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think I'm still probably a nerdy introvert at heart. I would probably</p>
</details>

**Nicolai Tangan:** 嗯，您隐藏得很好。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, you hiding it well, read books.</p>
</details>

**Vas Narasimhan:** 是的，没错。我想我学会了变得更具适应性，并且，你知道，看看如何最好地发挥每种情况的优势。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, exactly. I think I've learned to be more more adaptable uh and and sort of uh you know, see see how best to bring I think the best out of every situation.</p>
</details>

**Vas Narasimhan:** 我不知道是否有某个时刻，但首席执行官的工作肯定会推动你，对吗？它会把你推向不同的方向，因为你立即被推到如此多的不同利益相关者面前，学习这些不同利益相关者的语言，学习如何应对所有这些不同利益相关者。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um I don't know if there was a moment, but certainly the CEO job pushes you, right? it pushes you in directions because you're immediately, you know, thrust in front of so many different stakeholders u and learning the language of those different stakeholders, learning how to navigate all those different stakeholders.</p>
</details>

**Vas Narasimhan:** 你必须在过程中不断犯错，并希望你能够学习并变得越来越好，我认为这就是这个过程的展开方式。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um you have to fail at it as you go and hopefully you learn and get better and better and I think that's that's how the process obviously unfolds.</p>
</details>

**Nicolai Tangan:** 您提到了保持自身活力的重要性。您的能量来自哪里？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You mentioned um the importance of uh being energized yourself. Where do you get your energy from?</p>
</details>

**Vas Narasimhan:** 是的，我认为有几件事。我认为我们的人给了我巨大的能量。所以与他们互动，你知道，我深信我们所做的工作。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, I think I think our a few things. I think our people gives me a tremendous uh energy. So interacting interacting with them, you know, I I believe so deeply in the work that we do.</p>
</details>

**Vas Narasimhan:** 我总是，当我看到临床试验结果时，我仍然会哭，我很幸运能成为第一批看到结果的人之一，最终一种药物在三期临床试验中奏效了，因为我们所做的工作是如此艰难。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I I always still I still when I see a clinical trial result, which I'm very fortunate to be with the one of the first ones to see and it ultimately a medicine that worked in a phase three clinical trials, I cry because it is so hard to do what we do.</p>
</details>

**Vas Narasimhan:** 这是全球数千人可能超过十年集体努力的成果，然后我们得到了一个结果，我们确实为患有疾病的患者带来了改变，然后，你知道，你会说“让我们继续前进”，无论你遇到什么挫折，这都会给你能量。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">This is the collective work of thousands of people around the globe likely for over a decade and then we get a result where we actually move the needle for patients with a disease and then it you know you say let's keep going right in the face of whatever setbacks that you have that gives you energy.</p>
</details>

**Vas Narasimhan:** 患者来信，我非常幸运能收到那些药物改变了他们生活的患者的来信。我的意思是，所有这些事情都给了你一点点刺激，一点点推动，让你在作为首席执行官的一些更艰难的时刻坚持下去。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh letters from patients I'm very fortunate to get letters from patients who are are medicines uh whose lives they've transformed. I mean all of these things give you that little jolt, that little push to fight through some of the more trying moments of being a CEO.</p>
</details>

**Nicolai Tangan:** 但您也提到了您自己的身体健康等等，还有营养，您特别关注哪些方面？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But you mentioned also your own you you mentioned also your own physical health and so on just uh and nutrition and what are the kind of things you are particularly Oh yeah.</p>
</details>

**Vas Narasimhan:** 是的。所以，你看，我从我的教练斯科特·佩尔顿（**Scott Pelton**: 一位教练）那里很早就学到了这种**心态、运动、营养和恢复**（mindset, movement, nutrition, recovery: 个人健康和表现的四个关键支柱）的方法，我一直坚持着。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah. So look I I I got taught very early on from my uh a coach that I work with today named Scott Pelton this this this approach mindset, movement, nutrition and recovery and I stick with it.</p>
</details>

**Vas Narasimhan:** 所以心态，你知道，显然是**正念冥想**（mindfulness meditation: 通过专注于当下，培养觉察力和平静心境的练习），观察自己，观察你为什么会这样思考，为什么会有这样的感受，然后每天以及每次互动或每个时刻都让自己处于正确的心态，即使我必须出现在《In Good Company》播客上。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um so mindset you know clearly mindfulness meditation observing yourself observing why you think the things you think why you feel the things you do uh and then setting yourself up in the right mindset each day and for each interaction or each moment uh even when I have to show up on the in good company podcast.</p>
</details>

**Vas Narasimhan:** 嗯，你知道，营养，我认为你必须思考你为什么吃你吃的东西，以及你如何吃会以微小的方式影响你的表现。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um you know nutrition you know I think you have to think why do you eat the things you eat and how you eat will affect your performance even in small ways.</p>
</details>

**Vas Narasimhan:** 所以这是我总是思考的事情，显然是运动，我的意思是运动对**神经系统**（nervous system: 身体的控制和通信系统）有很大的影响。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So something I always think about obviously movement I mean exercise has a lot of impact on the nervous system.</p>
</details>

**Vas Narasimhan:** 这些年来我了解到，运动可以重置你的**交感神经系统和副交感神经系统**（sympathetic and parasympathetic nervous system: 自主神经系统的两个主要分支，分别负责“战斗或逃跑”和“休息和消化”反应）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Over the years I've learned that exercise can reset your sympathetic and parasympathetic nervous system.</p>
</details>

**Vas Narasimhan:** 顺便说一句，领导力很大程度上归结为管理你的神经系统。当你的交感神经系统高度活跃时，你很可能不会做出好的决定。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">By the way so much of leadership comes down to managing your nervous system. You're likely not going to make a good decision when you're on high sympathetic drive.</p>
</details>

**Vas Narasimhan:** 当你处于更平衡的副交感神经状态时，你更有可能获得所需的所有信息。所以观察自己这一点非常重要。

<details>
<summary>View/Hide Original English</p>
<p class="english-text">When you're more balanced parasitic sympathetic, you're more likely to get all the inputs that you need. So observing that in yourself uh is is hugely important.</p>
</details>

**Vas Narasimhan:** 然后是恢复。这些年来我学到了睡眠的力量。我的意思是，我痴迷于优化我的睡眠。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then recovery. I've learned over the years the power of sleep. I mean, I'm obsessed with trying to optimize my sleep.</p>
</details>

**Vas Narasimhan:** 我有，你知道，**睡眠技术**（sleep technology: 帮助监测和改善睡眠的设备和软件）、**睡眠补充剂**（sleep supplements: 用于改善睡眠的膳食补充剂），各种各样的东西，真正想知道我如何才能获得七小时以上的高质量睡眠并恢复。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I've got, you know, technology, sleep technology, sleep supplements, all kinds of things to really say, how can I get seven plus hours of very high quality sleep and and recover.</p>
</details>

**Vas Narasimhan:** 所有这些事情都会随着时间的推移而累积，然后给你所需的能量。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And all of those things compound over time and then give you the energy you need.</p>
</details>

**Nicolai Tangan:** 嗯，您对这些事情考虑得很周到。您早上几点起床？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, you're very thoughtful about these things. When do you wake up in the morning?</p>
</details>

**Vas Narasimhan:** 我每天早上5:30起床。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I wake up 5:30 every day.</p>
</details>

**Nicolai Tangan:** 您吃的神奇成分是什么？您吃的最奇怪的东西是什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">What's the magic ingredient uh that you eat? What is your most kind of strange thing that you eat? Strange thing that I eat?</p>
</details>

**Vas Narasimhan:** 我吃的最奇怪的东西？嗯，如果有什么奇怪的话，我是一个终身**素食者**（vegetarian: 不吃肉类的人），所以我一生中从未吃过肉。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, if there's anything strange, I'm a lifelong vegetarian, so I've never had meat in my life.</p>
</details>

**Vas Narasimhan:** 所以，你知道，这可能很奇怪，也可能不那么奇怪。显然，有很多。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, you know, that may be strange, maybe not so strange. Obviously, there's many.</p>
</details>

**Nicolai Tangan:** 嗯，我的意思是，很多人在，我的意思是，印度有很多素食者，你知道，我的意思是，这很常见，对吗？您的父母。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, I mean, I mean, a lot of people in Well, I mean, India has a lot of vegetar, you know, I mean, it's very common, right? And your parent.</p>
</details>

**Vas Narasimhan:** 是的，确实如此。确实如此。是的。绝对如此。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, it is. It is. It is. Yeah. Absolutely.</p>
</details>

**Vas Narasimhan:** 你知道，没什么特别奇怪的。我的意思是，我每天早上都吃**乳清蛋白**（whey protein: 一种从牛奶中提取的蛋白质），每天两勺乳清蛋白。这是我开始一天的方式。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You know, nothing nothing really strange. I mean, I I I eat whey protein every morning. Two scoops of whey protein every day. It's kind of a a way I start my day.</p>
</details>

**Vas Narasimhan:** 我想不出还有什么神奇的。我的意思是，我确实尝试了一些各种补充剂，比如**南非醉茄**（ashwagandha: 一种草本植物，常用于传统医学），以及一些这样的东西。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, nothing else magical I can think of. I mean, I do I do I do try some of the uh the various supplements like ashwagandha and some of this stuff I have.</p>
</details>

**Vas Narasimhan:** 这可能都是**安慰剂效应**（placebo effect: 因相信治疗有效而产生的实际改善，而非治疗本身的药理作用），但尽管如此，我肯定会测试这些东西。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's probably all a placebo effect, but nonetheless, I I definitely I definitely test these things out.</p>
</details>

### 企业文化与领导力传承

**Nicolai Tangan:** 您如何定义诺华的企业文化？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">How would you define the corporate culture at Novartis?</p>
</details>

**Vas Narasimhan:** 你知道，我们称之为“**受启发、好奇、无层级**”（inspired, curious, and unbossed: 诺华的企业文化理念，强调员工的自主性、求知欲和使命感），这是我们在2017年我刚开始时制定的，我们一直坚持着。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">you know we we we call it inspired curious and unboss and that that was something that we put together in 2017 when I first started and we stuck with it.</p>
</details>

**Vas Narasimhan:** 它实际上非常扎根于许多心理学家的工作，他们真正理解对于**知识工作者**（knowledge workers: 主要从事信息处理、创造性思维和问题解决的员工）来说，有三件事真正能激励他们：**目标感**（purpose: 工作的意义和目的），这就是“受启发”；**成长与学习**（growth and learning: 个人和职业发展），这就是“好奇”；以及**自主性**（autonomy: 独立自主地做决定的能力），所以你能否在适当的指导和目标下创造一种“无层级”的环境。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And it's very much grounded actually in work by uh many psychologists who really understood for for knowledge workers three things really motivate knowledge workers a sense of purpose so that's inspired a sense of growth and learning and a sense of they're improving theself that's curiosity and a sense of autonomy so can you create kind of an unbossed environment with the appropriate, you know, uh, guide rails and objectives.</p>
</details>

**Vas Narasimhan:** 所以，这就是我们着手要做的事情。过程非常坎坷。我们来自一个非常自上而下、等级森严的文化。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, that's what we set up to out to do. It was very bumpy. We came from a very top- down, you know, much more hierarchical culture.</p>
</details>

**Vas Narasimhan:** 我认为我们取得了很大的进步，但我们仍然在辩论它。我总是告诉我的员工，我们辩论它很好。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, I think we've made a lot of progress, but we still debate it. And I always tell my people, it's great that we debate it.</p>
</details>

**Vas Narasimhan:** 只要我们在辩论文化，文化可能就会变得更好，我们可能就会思考我们希望如何相互互动。但这些是三个关键要素，我们一直坚持着。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And as long as we're debating the culture, the culture is probably getting better and we're probably thinking about how we want to interact with one another. But those are the three key elements and we stick with it.</p>
</details>

**Nicolai Tangan:** 但我的意思是，“无层级”听起来不怎么像瑞士风格。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">But I mean unbossed that doesn't sound very Swiss.</p>
</details>

**Vas Narasimhan:** 不，实际上我认为它是斯堪的纳维亚风格的。所以实际上你们应该为此居功。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">No, actually I think it's Scandinavian. So actually you guys probably should take the take the take the credit for it.</p>
</details>

**Vas Narasimhan:** 但这个理念是，你知道，你能否创造一种更像**服务型领导**（servant leader: 以服务他人为首要任务的领导者）的赋能文化。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The idea is but the idea is um you know can you it's more of a servant leader empowered culture.</p>
</details>

**Vas Narasimhan:** 所以你能否真正在组织的每个层面创造主人翁意识，领导者创造环境，消除障碍，创造清晰度，而这些是我学到的一些东西。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So can you actually create ownership at every level of the organization uh where the leader is creating the environment removing obstacles creating clarity and you and that's some of the things I learned.</p>
</details>

**Vas Narasimhan:** 我的意思是，“无层级”最初被严重误解了。它被解释为无政府状态，人们可以随心所欲。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean UNBOS initially was really misinterpreted. It was kind of interpreted as anarchy or and people can do whatever they want.</p>
</details>

**Vas Narasimhan:** 实际上，我们想说的是，我们有明确的目标，但我们希望创造一个高支持、高挑战的环境。你受到支持。你必须自己做决定，但我们也会挑战。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Actually, what we want to say is we have clear objectives, clear goals, but we want to create this high support, high challenge environment. You're supported. You got to make your own calls, but we challenge.</p>
</details>

**Vas Narasimhan:** 我们承担责任，我们期望结果。如果你能做到这一点，它真的会推动绩效。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We hold accountability and we expect results. And if you can get that right, it really really drives performance.</p>
</details>

**Vas Narasimhan:** 我看看过去三四年，我们在**股东总回报**（TSR: Total Shareholder Return，衡量股票投资总回报的指标）和增长方面一直位居榜首，所以它得到了回报，但这无疑是一段漫长的旅程。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">and snap and I look at the last you know three three four years we've been at the top of the league tables on TSR and growth um so it's paid off but it's been a long journey for sure.</p>
</details>

**Nicolai Tangan:** 印度培养了一些我们今天世界上最令人印象深刻的领导者。您认为您的印度背景在任何方面影响了您的领导风格吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">India has produced some of the most impressive leaders we have in the world today uh has your your Indian background you think informed your leadership style in any way</p>
</details>

**Vas Narasimhan:** 我认为是的。我的意思是，我是在一个非常哲学化的环境中长大的。我的祖父母和父母都是虔诚的印度教徒，但也总是试图让我们接触哲学思想。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I do I think I think yes I mean I was I was raised uh kind of very phil in a very philosophical environment um my grandparents and my parents uh all all deeply Hindu but also always trying to uh expose us to philosophical um thinking.</p>
</details>

**Vas Narasimhan:** 所以即使到今天，我也会说一些最好的领导力书籍是像《薄伽梵歌》（**Bhagavad Gita**: 印度教经典之一，探讨哲学和精神）或《道德经》（**Dao Ching**: 中国古代哲学经典）这样的书，它们真正谈论的是服务型领导或寻找目标感和方向。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so even to this day I would say some of the best leadership books are books like the Bhagavat Gita or the Dao Ching which really talk about servant leadership or finding a sense of purpose and and and direction.</p>
</details>

**Vas Narasimhan:** 所以我认为它肯定有很强的指导作用。我认为当你观察**移民父母**（immigrant parents: 移居到新国家的父母），他们必须从一无所有的地方奋斗，经历那种经历，我认为这无疑会从小培养韧性和决心。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think it certainly had a very strong guide. I think also when you observe immigrant parents who have to come up and and fight for everything from where they come from very little and living that experience I think certainly you know builds resilience and determination as as a child for sure.</p>
</details>

**Nicolai Tangan:** 在印度，即使是神也必须谦逊。您，您谦逊吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well in India even the gods have to be humble. Are you um are you humble?</p>
</details>

**Vas Narasimhan:** 我谦逊吗？这就像一个陷阱问题。我有时觉得我努力做到谦逊。我努力，可以说，脚踏实地。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Am I humble? That's like a trick question. I sometimes feel like I think I try to be I try to be humble. I try to, let's say, keep my feet rooted in the ground.</p>
</details>

**Vas Narasimhan:** 我认为作为首席执行官最困难的事情之一是，很容易迷失在这一切中，对吗？很容易认为，不将你作为一个人与角色分开。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think one of the hardest things as as a CEO is it's easy to get lost in all of it, right? It's easy to think um not separate who you are as a person with the role.</p>
</details>

**Vas Narasimhan:** 这是一个角色，对吗？这是一个我们有幸在生命中的一段时间里扮演的角色，但它不是你。所以，你必须保持脚踏实地。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's a role, right? It's a role we have the honor to play for a period of time in our lives, but it's not not who you are.</p>
</details>

**Vas Narasimhan:** 我认为家庭非常重要。我有一个了不起的妻子，很棒的孩子，很棒的父母，他们让我脚踏实地。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So, you have to keep staying grounded. I think family is super important. I have an incredible wife, great kids, great parents that keep me grounded.</p>
</details>

**Vas Narasimhan:** 但你必须保持脚踏实地，否则这些角色会让你滋生自负，你会真正迷失。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh but you have to stay grounded otherwise these roles can you know build up an ego um and and you get really lost.</p>
</details>

**Vas Narasimhan:** 实际上有一本关于这个的伟大书籍，叫做《权力悖论》（**The Power Paradox**: 探讨权力如何影响人的行为和道德），作者是凯尔纳博士（**Dr. Kelner**: Dacher Keltner，加州大学伯克利分校心理学教授），他谈论了不受约束的权力如何让你失去同理心、考虑，你会失去对谦逊的理解，你会失去那些实际上让你有机会成为领导者的东西，这很讽刺。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">There's a great book about this actually called the power paradox um from yeah Dr. Kelner and he talks about how unchecked you know power will you will lose your empathy considerations you'll lose your understanding of humility um and you'll lose the very things that actually afforded you the opportunity to be a leader ironically.</p>
</details>

**Nicolai Tangan:** 是的，我同意，这是一本非常非常好的书。那么，您读什么书？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">yeah it's a I agree it's a very very um it's a very good book um now um what do you read?</p>
</details>

**Vas Narasimhan:** 我是一个非虚构类书籍的忠实读者。你知道，现在我正在读尤瓦尔·赫拉利（**Yuval Noah Harari**: 以色列历史学家，著有《人类简史》等书）的《智人：人类简史的下一章》（**Nexus**: 尤瓦尔·赫拉利2024年出版的新书，探讨人工智能与人类未来）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I'm I'm a big non-fiction reader um you know right now I'm I'm working my way through Nexus uh from Uvil Noah Harari.</p>
</details>

**Vas Narasimhan:** 嗯，你知道，我认为，非常有趣的作者，而且经常，你知道，从那些书中获得很棒的见解。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um you know I think uh very interesting author and often you know great great insights from from those books.</p>
</details>

**Vas Narasimhan:** 嗯，我的意思是，可能我最喜欢的一本书是史蒂芬·平克（**Steven Pinker**: 认知心理学家，著有《当下的启蒙》等书）的《今日启蒙》（**Enlightenment Now**: 史蒂芬·平克2018年出版的著作，论证人类在许多方面都在进步），它基于数据表明，尽管我们在新闻中读到所有挑战，但我们生活在人类历史上最伟大的时刻。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, some I mean probably my my favorite uh one of my favorite books is uh Enlightenment Now by Steven Pinker which is grounded in the data that we live despite all of the challenges we read about in the newsfeed we live in the greatest moment in human history.</p>
</details>

**Vas Narasimhan:** 如果我们能提醒自己这一点，并以科学为基础继续发展，这在当今世界并不容易，那么，是的，进步就在那里。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And if we can remind ourselves of that and keep building on that on a science-based way not easy in today's world um yeah that's that's where progress lies.</p>
</details>

### 给年轻人的建议

**Nicolai Tangan:** 最后一个问题，您会给年轻人什么建议？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">and and talking of which um last question what advice would you to young people.</p>
</details>

**Vas Narasimhan:** 是的，我想我希望不是一条建议，而是几条建议。第一，尽早培养**广度、深度和经验**（range, breadth and experience: 指在不同领域和职能中积累多样化的知识和技能）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yeah, I I think I wish not one piece of advice but a few pieces of advice. One, build range, build breath and experience early on.</p>
</details>

**Vas Narasimhan:** 我的意思是，尝试获得多样化的经验。这太诱人了，我也曾陷入想要快速晋升的陷阱。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, try to get diverse experiences. It's so tempting and I fell into the trap of wanting to race up the ladder.</p>
</details>

**Vas Narasimhan:** 实际上，诺华最终推动我走向了研发、营销、制造等各种横向方向，所有这些经验现在都使我能够胜任我现在的工作，尽管当时我没有意识到。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And actually it's such a and Novartis actually ended ended up pushing me into all kinds of lateral directions in in R&D in marketing in manufacturing and all of those experiences actually now enable me to do the job that I have right now though I didn't realize it at the time.</p>
</details>

**Vas Narasimhan:** 所以我认为，培养广度并获得不同的经验，包括职能、地理区域，甚至是您可能意想不到的事情。如果您以开放、好奇的心态去，您总会学到一些东西。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I think building range and getting different experiences, functions, geographies, uh even things you may not expect. You'll always learn something if you go in with an open, curious mindset.</p>
</details>

**Vas Narasimhan:** 嗯，我认为第二点是，这不是一场赛跑。我的意思是，感觉像是一场赛跑。但最终它不是一场赛跑。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um I think too, you know, there's not it's not a race. I mean, it feels like it's a race. It's not a race in the end.</p>
</details>

**Vas Narasimhan:** 你必须享受无论哪个方向的整个过程。而且没有计划。我从未想过会成为首席执行官。坦率地说，我职业生涯的大部分变动都不是我实际计划的。它们最终走向了不同的方向。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">You you got to enjoy the whole process of whatever direction. And there's no plan. I never expected to be a CEO. Most of my career moves were not the plan that I actually had, frankly. they ended up going in a different direction.</p>
</details>

**Vas Narasimhan:** 嗯，所以没有计划。这不是一场赛跑。你必须，听起来很老套，但你必须找到一种方法活在旅程的当下，同时显然还要不断推动自己前进。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Um, so there's no plan. It's not a race. You got to you've got It sounds cliche, but you've got to find a way to be in the moment of the journey while still obviously pushing pushing yourself uh forward.</p>
</details>

**Vas Narasimhan:** 然后找到优秀的**支持者**（sponsors: 在职业生涯中提供支持、指导和机会的人）。我的意思是，如果有些人没有在我身上下大赌注，我今天就不会在这里。你需要找到那些支持者。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then find great sponsors. You got I mean, I would not be where I am today if some people did not take huge bets on me. And you need to find those sponsors.</p>
</details>

**Nicolai Tangan:** 嗯，Vas，我很容易理解为什么人们会在您身上下大赌注。您显然拥有广度，您享受您所做的事情，您活在当下，是一位非常非常令人印象深刻的首席执行官。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Well, uh, Vas, I can easily understand why people have taken uh, huge uh, bets on you. uh you you clearly have the range, you enjoy what you do and and you are in the moment and uh a very very impressive CEO.</p>
</details>

**Nicolai Tangan:** 所以非常感谢您今天与我们在一起，祝您一切顺利。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So big thanks for for being with us today and all the best going forward.</p>
</details>

**Vas Narasimhan:** 非常感谢，辛克莱。能来到这里是我的荣幸。谢谢。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Thank you so much, Sinclair. It's an honor to be here. Thank you.</p>
</details>